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 Traumatic brain injury (TBI) is the most frequent cause of death in children and 
young adults in the United States.  Besides emergency neurosurgical procedures, there 
are few medical treatment options to improve recovery in people who have experienced 
a TBI.  Management of patients who survive TBI is complicated by both central nervous 
system and peripheral systemic effects.  The pathophysiology of systemic inflammation 
and coagulopathy following TBI has been attributed to trauma-induced endothelial cell 
dysfunction; however, there is little knowledge of the mechanisms by which trauma 
might impact the functions of the vascular endothelium at sites remote from the injury.  
The endothelium lining these small vessels normally produces nitric oxide (NO), 
arachidonic acid metabolites, and endothelial-dependent hyperpolarizing factors to relax 
the surrounding vascular smooth muscle.  For this research study we investigated the 
effects of fluid-percussion-induced TBI on endothelial-dependent vasodilatory functions 
in a remote tissue bed (the mesenteric circulation) 24 hours after injury.  We hypothesized 
that TBI causes changes in the mesenteric artery endothelium that result in a loss of 
endothelial-dependent vasodilation.  We found that vasodilations induced by the 
muscarinic-receptor agonist, acetylcholine, are attenuated following TBI.  While the 
endothelial-derived hyperpolarizing component of vasodilation was preserved, the NO 
component was severely impaired.  Therefore, we tested whether the loss of NO 
component was due to a decrease in bioavailablity of the NO synthase (NOS) cofactor 
BH4, the NOS substrate L-arginine, or to changes in expression/activity of the enzyme 
arginase, which competes with NOS for L-arginine.  We found that supplementation of 
L-arginine and inhibition of the enzyme arginase rescues endothelial-dependent 
vasodilations in TBI arteries.  This study demonstrates that there are pathological 
systemic effects outside the point of injury following TBI leading to a dysfunctional 
endothelial vasodilatory pathway.  These data provide insight into the pathophysiology 
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
1.1. Epidemiology  
Traumatic brain injury (TBI) represents the leading cause of morbidity and 
mortality worldwide in individuals under the age of 45, and is increasingly recognized as 
a major health care problem in the United States [73].  According to the US Department of 
Health and Human Services, there are approximately 1.7 million TBIs each year, resulting 
in 52,000 deaths, 275,000 hospitalizations and 1,365,000 emergency department visits 
[33].  The reported data may underestimate the true amount of TBI-related injuries due to 
possible misdiagnosis, unreported outpatient treatment, and patients who do not seek health 
care after injury.  Despite increased helmet use and safety measures, recent data indicate 
increasing emergency department visits for TBI in the US; this may be due in part to 
increased awareness, exposure, and diagnostics [76].  People who survive brain injury can 
suffer from long-term effects diminishing their productivity and overall quality of life. It 
has been estimated that more than 124,000 additional people each year will suffer from 
significant long-term disabilities after severe brain trauma [117].  Some individuals 
develop dementia and chronic traumatic encephalopathy from more mild, often repetitive, 
concussions [117]. Long-term effects can also arise from TBI and can include pathological 
manifestations such as seizures, epilepsy, neurodegeneration and Alzheimer’s disease [32].  
Thus, the total cost to society and to our health care system from TBI is enormous.   
The most common mechanism of injury resulting in a TBI is through a fall, but this 
is most prevalent in older adults [33]. Motor vehicle accidents, almost as common, account 
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for the largest proportion of TBI-related deaths [33]. Sports and recreational activities are 
also a major cause of TBI.  Sports related mild TBI does not always involve a loss of 
consciousness and can go unrecognized and uncounted.  It has been estimated that 1.6 to 
3.6 million sports related TBI occur every year and can cause long term cognitive problems 
[70].  Another major risk factor for TBI is military combat, particularly in recent times with 
warriors wearing Kevlar helmets and sustaining blast injuries from improvised explosives.  
In a survey of U.S. Army infantry soldiers, 15.2% reported blast injuries in which they 
suffered either a loss of consciousness or altered mental status during deployment; of note 
these individuals were at substantially higher risk for post-traumatic stress disorder [50].  
Children between the ages of 0-4 and adults over the age of 75 years have the 
highest rate of TBIs [10]. Males appear to have more TBIs, with a higher rate of 
hospitalization, emergency visits and deaths related to TBI than the female population [33] 
who appear to be protected by the hormone progesterone [2,27].  
 
1.2. Clinical classification  
A TBI is defined as an injury to the brain, caused either by blunt trauma, penetrating 
trauma, rapid motion or blast injury to the cranium which leads to a disruption of regular 
cerebral function [96].  TBI can range from mild to severe, and while there are multiple 
ways to classify TBIs, they all suffer from limitations.  Currently, the most common scoring 
system for severity of brain injury is the Glasgow Coma Scale (GCS), which classifies 
injuries as mild, moderate or severe, by scoring the level of consciousness at first medical 
contact after a head trauma [73].  The score is the sum of three physical exam findings: 
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eye, motor and verbal reflexes.  A GCS score of 13, 14 or 15 defines “mild TBI”, typically 
a brief change in mental status or consciousness, and interchangeably called “concussion”.  
“Moderate TBI”, with GCS score of 9-12 [73], predicts a higher probability of permanent 
disability.  GCS scores of 3-8 define “severe TBI”, typically presenting with an extended 
period of unconsciousness and coma, and predict a high risk of death [73].  Other similar 
scoring systems based on clinical findings include the injury severity score, Brussels coma 
scale, Grady Coma Scale, and Innsbruck coma scale.  
After neuroimaging (typically, non-contrast computed tomography scan of the 
brain), brain trauma is described clinically by anatomic location and pattern of injury. 
Severe TBI can be heterogenenous, and there are at least 6 different patterns of injury that 
can result in GCS < 8 [96]. Patterns include subdural hematoma, cerebral contusion, or 
subarachnoid, intraparenchymal, or intraventricular hemorrhage, with or without brain 
edema or “midline shift” [96].  Diffuse axonal injury without bleeding can also result in 
coma and death, but can only be seen on magnetic resonance imaging (MRI). Severity 
classifications can also be made according to the patho-anatomic classification of injury, 
describing the location, anatomical features of injury and size of lesion. The Marshall Score 
is based on CT scan results, and can be used to predict the risk of increased intracranial 
pressure and outcome in adults [74].   
There are several clinical tools that are used to measure clinical outcomes in 
patients who survive TBI. The Glasgow outcomes score (extended), and disability rating 
scale, have been used to describe clinical outcomes or neurologic injury severity [74]. 
Unfortunately, there are currently no diagnostic tools that can accurately predict outcomes 
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after a TBI. Current methods of classifying TBI do not take into account the subsequent 
secondary systemic effects that may occur during the recovery period following TBI.   
 
1.3 Pathophysiology 
TBI is a heterogeneous disease that has variable pathophysiological outcomes 
which compound the issue of diagnosis and treatment.  As described in the section above, 
injury can be classified by the physical mechanism of impact (blunt, penetrating, rotational, 
or blast), pathoanatomic features, and clinical findings.  Primary injury to brain structures 
by any mechanism happens immediately and is a direct result of mechanical trauma [73].  
Tissue damage may include shearing of white matter, focal bleeding, swelling within gray 
matter, hematomas, microporation of membranes, and vascular injury [60,74].  The 
physical mechanism of impact can predict the type and severity of the tissue injury.  
Different mechanisms such as direct impact, rapid acceleration or deceleration, penetration 
(gunshot) or blast waves from an explosion  produce typical patterns of tissue damage [74].   
Diffuse axonal injury, with multiple lesions or shearing of white matter tracts, occurs most 
commonly through an acceleration/deceleration mechanism [52]. 
Secondary insults after TBI can arise hours to days later and may involve the release 
of neurotransmitters (glutamate), ion channel leakage, reactive oxygen species (ROS) 
production, blood brain barrier (BBB) breakdown, edema and increased intracranial 
pressure (ICP) [31,73,74,82].  Progression of intracranial hemorrhage and progressive 
edema are the most common secondary insult following an initial traumatic injury [96]. 
Common secondary changes that occur to the brain after TBI also include progressive 
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white matter changes (after axonal injury), reactive gliosis, and degeneration of neural 
tissue and Tau protein accumulation, which has been associated with chronic traumatic 
encephalopathy [13]. The most common form of TBI is diffuse axonal injury where there 
are multiple lesions or shearing of white matter tracts and occurs most commonly through 
acceleration/deceleration impact such as a car accident [52].  Although the primary brain 
injury is untreatable from the standpoint of the clinician, secondary effects of TBI may be 
avoidable and are of major interest to researchers and health care providers.  
The cerebral circulation appears highly vulnerable to secondary pathophysiological 
effects after TBI.  One of the most important physiological properties of the cerebral 
circulation is cerebral autoregulation which is the mechanism that maintains cerebral blood 
flow (CBF) constant despite changes in cerebral perfusion pressure [91].  Cerebral 
autoregulation is maintained by myogenic, neurogenic, and metabolic mechanisms. The 
myogenic component is defined as the inherent mechanism of vascular smooth muscle cells 
(VSMCs) to constrict or dilate in response to changes in intramural pressure [91].  Multiple 
studies have demonstrated that more than 50% of TBI patients have shown an impairment 
in autoregulation [31,40,55,91].  Disrupted autoregulation is often associated with a high 
mortality rate and poor outcome in TBI survivors, even in minor brain injuries [96]. The 
loss of cerebral vascular autoregulation increases the susceptibility of harmful secondary 
effects such as hypoxia, ischemia and infarction [49,91].  Time course studies show that 
within 3-5 days post-injury, over 80% of patients display an impaired autoregulation [105].  
Patients who were unable to reestablish a normal autoregulation after two weeks had 
unfavorable outcomes that correlated with a low GCS score, diffuse brain injury and 
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elevated ICP [105].  Changes in cerebral vascular tone and vasodilation are due at least in 
part to changes in endothelial NO production [111].  The loss of vascular compensation in 
response to reduced cerebral blood flow can result in regional ischemia and often results 
in death. TBI can also have effects on the permeability properties of the cerebral vessels, 
contributing to edema [102].  
The BBB which is responsible for maintaining homeostasis between blood 
circulation and the central nervous system could be compromised in TBI [102].  This 
breakdown may last from several days to weeks or even years after injury occurs and the 
extent of damage is directly related to the method of injury [107].  Primary damage to the 
brain can lead to injured endothelial cells, leaky channels, a loss of vascular integrity and 
metabolic processes [95].  BBB breakdown may occur as a result of initial injury or 
secondary effects such as inflammation or metabolic disturbances.  Secondary brain 
damage that arises from BBB breakdown includes increased endothelial permeability 
which leads to brain edema [102].  Edema that emerges from TBI can lead to fluid 
accumulation in the brain and can lower perfusion of cerebral blood flow, exacerbating 
detrimental effects to the TBI survivor [73,102].    
Along with cerebral complications, systemic complications can also arise from TBI 
such as hypertension and coagulopathy [62,118].  Many of the systemic effects seen after 
TBI including increased blood pressure, cardiac output, deregulated temperature, 
metabolic changes, and oxygen utilization are associated with increased levels of 
circulating catecholamines [18,19,51].  Studies have shown that there is an increased 
sympathetic discharge, with a large amount of catecholamines release (norepinephrine, 
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epinephrine, and dopamine) in circulation following TBI; the amounts of circulating 
catecholamines present correlates with a lower GCS and more severe injury [19].  
Sustained sympathetic hyperactivity peaking 1-3 weeks after injury and elevated 
circulating catecholamines also predict poor outcome and increased mortality rate 
[18,19,46,93].  Some individuals who sustain a TBI may develop a rare and severe 
complication called a paroxysmal sympathetic hyperactivity syndrome “sympathetic 
storm” [88]. Patients who suffer from sympathetic storm experience bouts of tachycardia, 
hypertension, sweating and increased respiration that often occurs in waves and correlates 
with an elevation of ICP [88]. The pathophysiology of sympathetic storm requires further 
study, but is likely related to damage to parts of the brain that control autonomic nervous 
system functions. 
The sympathetic hyperactivity response from TBI can mediate cardiovascular 
abnormalities and myocardial dysfunction [41,45]. These abnormalities lead to increased 
blood pressure, increased pulse, tachypnea, cardiac contractility, increased troponin levels 
and abnormal ECGs which may contribute to mortality [15,71,75].  In patients who endure 
a head injury, 20-30% with subarachnoid hemorrhage will subsequently suffer from 
cardiomyopathy, this has been referred to as neurogenic stress cardiomyopathy (NSC) [15].  
Patients with NSC are at particularly high risk for potentially fatal complications such as 
ventricular arrhythmias and SAH-associated cerebral vasospasm. ECG abnormalities are 
observed in 75-92% of patients with intracranial bleeding [15].  Cardiovascular effects of 
TBI has been described in a rat model where they reported myocardial damage from TBI; 
myocytolysis, contraction band necrosis, edema formation and interstitial mononuclear cell 
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infiltration was seen in cardiac myocytes taken at different time periods following TBI 
[85].  In the 24 hour trauma group, TEM analysis of cardiac myocytes showed swollen 
mitochondria, dilated sarcoplasmic reticulum and large edematous areas of the cytoplasm 
with significantly levels of nuclear damage [85].  Sympathetic release of catecholamines 
may cause cellular stress and damage by generating ROS and forming oxidation products 
[92].  ROS have also been reported in cardiac tissue in a TBI rat model produced by our 
laboratory [71].  TBI affects not only the central area of impact but can also damage 
peripheral organs such as the cardiovascular system resulting in cellular damage and 
increased mortality.  
There have been numerous clinical trials for TBI over the years including 
corticosteroids [67], hypothermia [6], and progesterone [113], but few treatment options 
have been shown to decrease the secondary effects of TBI.  One promising area of research 
is with beta adrenergic receptor antagonists (β-blockers) for treatment of TBI [4].  
Adrenergic receptor antagonists may be used to try to control the sympathetic hyperactivity 
that follows TBI, and can reduce the impact of sympathetic stimulation by regulating 
hypertension and cardiac output [4].  In a large retrospective review, TBI patients who 
happened to be on β-blockers prior to their head injury had a statistically decreased 
mortality rate compared to those who were not [20].  In another study of TBI survivors 
with a GCS of 5, treatment with  propranolol lowered their increased metabolic expenditure 
and hypertension [93].  Decreasing TBI-induced systemic hypertension could protect TBI 
survivors from developing cerebral edema and improve cerebral autoregulation. However, 
prospective studies of adrenergic receptor blockade for TBI are needed to determine if 
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these drugs are a suitable treatment to improve long-term outcome.   Despite the extensive 
literature on secondary cardiovascular effects after TBI, there are no studies focusing 
specifically on effects of TBI in systemic blood vessels and particularly the endothelium.  
 
1.4 Endothelial Vasodilatory Functions 
The endothelium is a single layer of cells which lines the intraluminal space inside of 
blood vessels. The endothelium has specialized tight junctions, serving as a physical barrier 
between circulating blood cells and the extravascular or interstitial space.  More than just 
providing a physical barrier, the endothelium plays a larger role in cardiovascular 
physiology; it modulates inflammatory responses, coagulation, angiogenesis, and vessel 
diameter.  Small resistance sized arteries with diameters less than 200 microns play a 
critical role in the regulation of peripheral vascular resistance and dysregulation of vascular 
tone which may contribute significantly to high blood pressure [63].  The focus of this 
section will be specifically on the multiple factors released by the normal endothelium in 
resistance size arteries that contribute to vasodilation and/or vasoconstriction processes. 
The role of the endothelium in relaxation of blood vessels has been extensively discussed 
and reviewed since its first appearance in the literature in 1980 by Furchgott [39].  It is 
now recognized that there are two main pathways involved in endothelial-dependent 
dilation of VSM, nitric oxide (NO) and endothelial dependent hyperpolarization (EDH).  
The products of cyclooxygenase activity also dilate some vascular beds but this pathway 
does not appear to play a role in dilation of resistance-sized arteries and therefore is not 
reviewed in this paper.  
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1.4.1 Nitric Oxide 
The involvement of NO in vascular function was first described by Furchgott and 
Zawadski in 1980 and was initially called “endothelial derived relaxing factor” or EDRF 
[39].  EDRF was shown to be released by the endothelium upon activation by ACh; sodium 
nitroprusside (SNP), glyceryl trinitrate and NO mimic the response to ACh on the 
muscarinic receptor.  It was determined later that NO and EDRF were the same species, 
shown by similar concentration curves and decay rates [86].  
NO is a vascular protective chemical, i.e. it protects from accumulation of platelets 
and plaque formation, inhibits proliferation of  VSMC and decreases expression of genes 
that engage in the proinflammatory response [38].  Endothelial cells synthesize NO by 
endothelial nitric oxide synthase (eNOS), a Ca2+-dependent isoenzyme that may be 
constitutively active, but is primarily activated by G-protein coupled receptor activation or 
by shear stress induced by increased blood flow. This in turn activates eNOS through a 
Ca2+-dependent mechanism [35].  eNOS converts L-arginine to L-citrulline releasing NO, 
in the presence of the cofactors Tetrahydrobiopterin (BH4), oxygen, Flavin adenine 
dinucleotide (FAD), and nicotinamide adenine dinucleotide phosphate (NADPH) [38].  NO 
diffuses into the VSM and activates soluble guanylyl cyclase (sGC) which converts 
guanosine triphosphate to cyclic guanosine monophosphate (cGMP), activating cGMP-
dependent protein kinase (PKG) and promoting vasodilation.  PKG has multiple targets in 
the VSMC.  PKG general targets include 1) L-type Ca2+ channels on the plasma membrane, 
which causes them to inactivate, 2) phospholamban on the sarcoplasmic reticulum (SR) 
releasing its inhibition of the sarcoplasmic reticulum Ca2+ ATPase and thereby increasing 
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Ca2+ uptake from the cytosol, 3) IP3 receptors on the SR which inhibit release of Ca2+, and 
4) VSM large conductance Ca2+ activated K+ channels (BKCa).  These events all lead to 
decreased intracellular calcium [Ca2+]i  and vasodilation [23,36-38,42].  
 
1.4.2 EDHF in the vascular endothelium 
Endothelial-dependent hyperpolarization factor (EDHF) is an endothelial function 
that can hyperpolarize and subsequently relax VSMC independently of NO and 
prostacyclins.  It involves the endothelium, and incorporates specifically endothelial Ca2+-
activated potassium channels (KCa) [14].  There is a variation in the nature and mechanisms 
of EDHF among different vascular beds and species. EDHF can be activated by agonists 
such as ACh, bradykinin, histamine or substance P causing hyperpolarization and 
subsequent VSMC relaxation by decreasing cytosolic Ca2+ [68].  The EDHF-mediated 
pathway in rat mesenteric arteries involve KCa, specifically: small conductance (SKCa) and 
intermediate conductance (IKCa) potassium channels [14,30,62,68,77].  SKCa and IKCa 
channels have a Ca2+ dependent relationship that is mediated by calmodulin, and lack 
voltage sensitivity.  In experimental preparations, the EDH component of ACh-induced 
dilation can be evaluated using pharmacology to block KCa with charybdotoxin (BKCa and 
IKCa channel blocker) and apamine (SKCa channel blocker) [68].  Of note, apamine and 
iberiotoxin (BKCa channel blocker) are unable to prevent SMC hyperpolarization and ACh-
induced vasodilation [26].  This finding introduced confusion until it was later discovered 
that while apamin and iberiotoxin together can completely abolish SKCa and BKCa channel 
ion flow, neither can block IKCa channels.  Charybdotoxin is thus used to block not only 
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BKCa but also IKCa channels.  Together, SKCa and IKCa channels in the endothelium appear 
to account for the EDH component of ACh induced vasodilation. 
 ACh activates muscarinic receptors on EC surface and induces a release of Ca2+ 
from the ER through IP3 channel activation.  As a result, increased [Ca2+]i   triggers SKCa 
and IKCa (and also eNOS) to cause efflux of  K+ out of the EC and into the myoendothelial 
space.  The increased concentration of K+ in the myoendothelial space activates VSMC 
internally rectifying potassium channels (KIR), causing VSMC hyperpolarization and 
relaxation [34].  Hyperpolarization of VSMC deactivates voltage dependent calcium 
channels (VDCC), reducing Ca2+ influx and Ca2+ affinity of contractile proteins for Ca2+.  
Recent results indicate that in mouse mesenteric arteries the transient receptor 
potential vanalloid 4 (TRPV4) channels plays an important role in amplification of the ACh 
response [103].  Hyperpolarization of the endothelium elicits TRPV4 mediated influx of 
extracellular Ca2+.  TRPV4 channels are the predominant extracellular Ca2+ influx pathway 
involved in the vasodilation of mouse mesenteric arteries in response to ACh and 
contributes approximately 75% to VSMC hyperpolarization and vasodilation [28].  
Activation of few TRPV4 can lead to maximal vasodilation, in part due to the localization 
of these signals at microenvironments in the myoendothelial projections. Increases of 
[Ca2+]i through activation of TRPV4 also stimulate BKCa channels through ryanodine 
receptor mediated Ca2+ sparks inducing vasorelaxation [28].   
Endothelial cell hyperpolarization may be transferred to the VSMC via gap 
junctions within these myoendothelial projections, as suggested by the fact that inhibition 
13 
 
of gap junctions by anti-connexin antibody decreases endothelial-dependent relaxation 
[30].  Microdomain environments exist between SKCa and KIR, and IKCa and K+/Na+-
ATPases [30] and can contribute to the cooperation of KCa channels to maintain a balanced 
response to shear stress, receptor agonists and electrochemical changes in the cell.  
Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid through the 
CYP enzymatic pathway and are candidates for EDHF.  ETTs are synthesized in 
endothelial cells and cause hyperpolarization of VSMC through the activation of large 
conductance BKCa channels [63].  Previous studies show that mouse mesenteric arterioles 
rely on TRPV4-mediated activation of the EETs pathway to cause hyperpolarization and 
subsequent vasodilation of resistance arteries [68].  EETs-induced vasodilation can be 
inhibited by ChTx, the BKCa IKCa channel blocker, suggesting its role in the EDHF pathway 
[68,80].  
Hydrogen peroxide (H2O2) has also been reported to cause relaxation in vascular 
tissue depending on the arterial bed.  H2O2 can cause vasorelaxation in mouse mesenteric 
arteries and may act as an EDHF [29].  This was shown in small mouse mesenteric artery 
dilation where ACh induced hyperpolarization was abolished with incubation of catalase 
in the absence of NO and COX derived pathways [78].  
 The contribution of EDHF to vasodilation has been extensively studied, and the 






1.5 Endothelial Dysfunction 
  Endothelial dysfunction was first described by Furchgott and Zawadski when they 
observed an attenuated response to ACh after accidently rubbing the intraluminal layer of 
a rabbit aorta [39].  They concluded that arterial relaxation by ACh required the presence 
of endothelial cells [39].  Endothelial dysfunction has been described in a variety of 
vascular related diseases such as diabetes [97], atherosclerosis [65], ischemia-reperfusion 
[77], and hypertension [63].  Endothelial dysfunction is typically defined as an impaired 
vasodilatory response to the muscarinic receptor agonist, ACh.  Mechanisms that impair 
the vasodilatory function of the endothelium include oxidative stress, impairment of NO 
production (through eNOS uncoupling, increased arginase activity, or depletion of 
tetrahydrabiopterin), and impairment of EDHF induced-hyperpolarization.  Evidence for 
each of these mechanisms in endothelial dysfunction is provided below.   
 
1.5.1 Reactive oxygen species (ROS) 
Oxidative stress and reactive oxygen species (ROS) have been common variables 
in endothelial dysfunction.  ROS are produced under normal conditions in the cell 
through multiple enzymatic pathways such as eNOS, COX, lipoxygenase, cytochrome 
P450, and NADPH oxidases [38].  Disruption to theses enzymes can lead to uncoupled 
behavior resulting in an increase production of ROS [83].  NADPH oxidase has been 
implicated in the production of the superoxide anion (O2-), which in turn reacts with 
eNOS-derived NO to form peroxynitrite (ONOO-).  ONOO- has been shown to cause 
damage to endothelium through peroxidation of lipids, sulfhydryl groups, tyrosine groups 
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and guanine groups [94].  Accumulating amounts of ONOO- can uncouple eNOS by 
oxidizing the Zn-thiolate in the enzyme and its cofactor tetrahydrobiopterin (BH4), 
dissociating the monomers, reducing NO bioactivity and uncoupling eNOS [94].   NOS in 
an uncoupled state results in an electron transfer to oxygen instead of  its substrate L-
arginine, creating ROS [83].  Formation of ONOO- has also been shown to inhibit sGC 
and inactivate prostacyclin synthase by tyrosine nitrosylation [38,94,120].   
ROS, particularly O2- are believed to contribute to the pathophysiology of 
hypertension by reducing the bioavailability of NO.  ROS have also been implicated as a 
mechanism of cerebrovascular dysfunction following TBI [6].  ROS also act on vascular 
ion channels, including VSM L-type Ca channels and endothelial SK channels [3,16].  ROS 
production in vascular disease can inhibit all three of the primary endothelium-dependent 
vasodilator pathways (NO, EDH and prostacyclin) and tilts the balance of the endothelium 
towards constriction.  
 
1.5.2 Uncoupling of eNOS 
 Under pathological conditions, eNOS can act in an uncoupled mode producing 
oxygen radicals that contribute to vascular diseases such as diabetes [100], hypertension 
[69], atherosclerosis [101], and obesity [116].  The “uncoupled” eNOS enzyme donates 
electrons to O2 instead of L-arginine, thereby producing superoxide rather than its usual 
product NO.  O2-. can react with NO producing peroxynitrate (ONOO-) which decreases 
NO bioavailability [94].  Oxidation of the eNOS zinc-thiolate cluster by ONOO-  can 
uncouple eNOS [38].  In a study conducted on DOCA-salt treated hypertensive mice, ROS 
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production was lowered by inhibition of NOS and knocking down nicotinamide 
dinucleotide phosphate oxidases (NOX), suggesting that NOX activity produces ROS and 






1.5.3 Role for L-Arginine and arginase in eNOS uncoupling 
Figure 1 Schematic of eNOS uncoupling: Endothelial nitric oxide synthase (eNOS) can become 
uncoupled through multiple factors such as a decreased amount of its cofactor BH4, increased 
reactive oxygen species (ROS) and decreased amounts of its substrate L-arginine. In an uncoupled 
state eNOS produces superoxide (O2-) anions which then scavenge NO, producing peroxynitrite 
molecules which further uncouple the enzyme. Decreased NO can then lead to increased 
vasoconstriction of the artery.  
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L-arginine is the rate-limiting substrate in the enzymatic production of NO 
through eNOS.  Decreased L-arginine has been shown to contribute to eNOS uncoupling 
and lead to disruption of endothelial-dependent vasodilatory function [53].  Under 
pathological conditions, L-arginine supplementation has been shown to restore endothelial 
dependent dilation [53].  In example, it has been demonstrated that ACh-induced 
vasodilations are decreased after successive concentration response curves were performed 
on the same artery [53]; this attenuated response to ACh on the 2nd and 3rd treatment is due 
to the depleted stores of endothelial derived L-arginine which can be rescued by 
supplementation of L-arginine [53]. 
Arginase is a major consumer of L-arginine and can compete for L-arginine in the 
vascular endothelium, uncoupling eNOS [38].  Increased arginase activity has been 
reported to contribute to endothelial dysfunction in multiple diseases such as aging [8], 
ischemia–reperfusion [47], hypertension [57], atherosclerosis [115], diabetes [101] and 
obesity [44].  These studies show that arginase plays an important role in regulating NO 
bioavailability by competing with eNOS for L-arginine  [8,44,47,57,101,115].  Arginase 
inhibition can help restore dysregulated endothelial function by increasing eNOS 
dependent NO production in the endothelium. A specific inhibitor of arginase, nor-NOHA, 
an analog of an intermediate in the conversion from L-arginine to NO which interrupts its 
Mn-cluster active site [21] has been shown to rescue dysfunctional endothelial-dependent 
vasodilations in arteries [44,101].   
In a diet induced obesity model, mouse aortas from high fat diet mice showed an 
increase in arginase expression and a decreased expression of eNOS when compared to 
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low fat diet mice aorta [44].  Inhibition of arginase by nor-NOHA restored NO levels in 
the aorta of high fat diet mice [44].  Rescue of endothelial-dependent vasodilations have 
also been shown in patients diagnosed with type-II diabetes mellitus and coronary artery 
disease who displayed elevated levels of arginase expression [101].  Infusion with the 
specific arginase inhibitor nor-NOHA restored vasodilatory responses to SNP and also 
increased eNOS expression in vascular tissue [101].  Supplementation of L-arginine or 
inhibition of the enzyme arginase can restore NO production in multiple disease states, 
providing a potential therapeutic target for cardiovascular disease.  
 
1.5.4 Tetrahydrobiopterin (BH4) and eNOS uncoupling 
A critical determinant of eNOS activity is the availability of its cofactor (BH4) 
[110].  Uncoupling of eNOS has been implicated in a number of diseases with decreased 
BH4 levels, including atherosclerosis, diabetes and hypertension [24,25,101].  Deficient 
BH4 availability in the endothelium has been correlated with decreased NO bioavailability, 
impaired cGMP, and vasoconstriction [110].  Under conditions of limited BH4 availability 
(due to oxidation or reduced formation), eNOS functions in its “uncoupled” state and 
NADPH-derived electrons are added to molecular oxygen instead of L-arginine, leading to 
the production of superoxide.  
BH4 is a reducing agent and can become a target for oxidation during cellular 
oxidative stress which in turn lowers its bioavailability.  Low levels of BH4 further 
contribute to an oxidative state which has been seen in high fructose-fed rats and 
hypercholesterolemic patients [110], and has been linked to hypertension [69].  Oral and 
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intravenous supplementation of the eNOS cofactor BH4  has been shown to lower 
intracellular levels of ROS and rescue ACh-induced endothelial-dependent vasodilation in 
vascular disease models [69,89,100].   
Supplementation of BH4 can be performed by introducing the BH4 precursor 
sepiapterin [100].  Sepiapterin can be reduced in all cells by sepiapterin reductase to 7,8-
dihydrobiopterin (BH2) and further by dihydrofolate reductase to form BH4 by the salvage 
pathway [84].  In obese mice, BH4 supplementation with sepiapterin rescued vasodilation 
in response to ACh, which was blocked by L-NAME [89].  Importantly, BH4 
supplementation in animals with these diseases improves endothelial dysfunction [110].  
 
1.5.5 EDHF 
EDHF is also thought to contribute to vascular dysfunction, in rat models of 
diabetes [72,112] and hypertension [64].  In a study in cultured human kidney cells, ROS 
could impair EDHF hyperpolarizations by directly inhibiting the function of BKCa channels 
in the VSMC by modifying a cysteine residue on BKCa channels and decreasing its 
sensitivity to Ca2+ [106].  The EDHF component of vasodilation can become altered in 
disease states and can lead to dysfunctional vasodilations in response to agonist 
stimulation.  In streptozotocin-induced diabetic rats, the role of EDHF and NO-type 
relaxations in mesenteric arteries was impaired shown by  decreased ACh-induced 
vasodilation in the presence of NO inhibitors and EDHF-associated channel blockers [72].  
In an angiotensin infusion induced hypertension model, ACh-induced vasodilations in 
mesenteric arteries resulted in attenuated responses compared to controls [64]; in that 
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study, inhibition of NOS with L-NAME completely abolished ACh-dilations in 
hypertensive mesenteric arteries, implying that the EDHF pathway was dysfunctional [64].   
 
1.6 Myogenic Tone in Resistance Arteries 
The myogenic response is the intrinsic ability of the VSMC to constrict or dilate in 
response to changes in intravascular pressure [5,91].  The myogenic response was first 
described in 1902 by Bayliss, when he noted that excised arteries would contract to  
increased intramural pressure and relax under lesser pressure independent of the peripheral 
nervous system [7].  Previous studies have shown that the strength of myogenic tone varies 
throughout vascular beds and can also be dependent on artery size in the same vascular bed 
[98].  
Mechanical stretch induced by increasing intraluminal pressure activates non-
selective stretch activated ion channels to elicit VSMC depolarization [98].  Changes in 
membrane potential in turn activate L-type calcium (Ca2+) channels, leading to influx of 
Ca2+ through these channels increasing intracellular Ca2+ ([Ca2+]i) [48].  Rising [Ca2+]i 
activates myosin light chain kinase (MLCK), which can then phosphorylate myosin light 
chain (MLC) allowing it to interact with ATP and bind to actin to contract VSMC.  Myosin 
light chain phosphatase (MLCP) removes the phosphate group from MLC inhibiting its 
interaction with ATP and prevents SMC contraction.  This mechanism allows for the 
detachment and reattachment of myosin to actin causing vasoconstriction [98]. BKCa 
channels also play a role in myogenic tone by providing a negative feedback mechanism 
to oppose vasoconstriction. Increased [Ca2+]i induces Ca2+ sparks, spatiotemporal increases 
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of cytosolic  Ca2+ released by ryanodine receptors found on the sarcoplasmic reticulum 
(SR) [12].  Ca2+ sparks activate BKCa channels and hyperpolarize the cell, inhibiting further 
constriction [12].  
Vascular tone can also function independently of increasing [Ca2+]i levels.  The 
ratio of MLCK and MLCP activity modulates MLC Ca2+ sensitivity; enzymes such as 
protein kinase C (PKC) or Rho-kinase (ROK) also contribute to this mechanism.  
Phosphorylation of MLCP by PKC or ROK can increase myogenic tone by inhibiting 
dephosphorylation of MLC, promoting SMC contraction. 
It is generally accepted that the endothelium has a role in modulating tone by 
releasing basal amounts of vasodilators like NO to oppose vasoconstriction. The 
involvement of the endothelium in regulating tone can vary in different species and 
vascular beds [17,59,79].  For example, a study showed that rat mesenteric arteries 
removed of endothelium (denuded) experienced no change in myogenic tone in response 
to step-wise increase in intraluminal pressure [104].  In contrast, denuded cerebral arteries 
had a profound increase in myogenic tone due to an endogenous endothelial NO production 
[111].  In the mouse, denuded mesenteric arteries had enhanced myogenic response, which 
was attributed to the loss of endothelial-dependent NO release [99].  The ability to develop 
and maintain myogenic tone is imperative in small resistance arteries, where loss of 
function or modulation is often correlated with the development of disease.   
 
CHAPTER 2: ENDOTHELIAL-DEPENDENT DILATIONS ARE 





TBI is the most frequent cause of death in children and young adults and is 
increasingly recognized as a major health care problem in the United States [73].  
Individuals who survive TBI may suffer from long term effects that will significantly lower 
the overall quality of life. TBI is a heterogeneous disease that has variable 
pathophysiological outcomes in the area of injury (the brain) and areas peripheral to injury.   
Along with cerebral complications, systemic complications can also arise from 
TBI.  Systemic effects induced by TBI include increased blood pressure, temperature 
imbalance, metabolic changes and increased oxygen utilization; all these effects can be 
correlated with an increased sympathetic discharge of circulating factors such as 
catecholamines [18,19,46,93].  Sympathetic hyperactivity induced by TBI has negative 
effects on the cardiovascular system, coagulopathy and acute lung injury [11,85,92,118].   
However, beyond cardiovascular effects, there are no data showing peripheral 
damage to the vasculature caused by TBI-induced circulating factors.  Arterial vasculature, 
especially small resistance arteries, plays an important role in regulating peripheral 
vascular resistance [60].  Increased vasoconstriction in resistance arteries may serve as a 
compensatory mechanism to maintain optimal circulatory efficiency and  redistribute blood 
flow between and within organs to maintain normal levels of blood pressure [43].    Basal 
constriction (myogenic tone) of vascular smooth muscle cells (VSMC) and relaxation 
through endothelial-dependent pathways are key factors in the regulation of blood flow [4].  
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The endothelium, a single layer of cells which lines the intraluminal surface of 
vessels, releases vasoactive factors that contribute to vasoconstriction and vasodilation.  In 
resistance arteries, there are two main endothelial-dependent pathways that lead to 
vasodilation: endothelial dependent hyperpolarizing factor (EDHF) and nitric oxide (NO).  
Dysfunctional endothelial-dependent pathways have been implicated in multiple vascular 
disease states such as diabetes, atherosclerosis, obesity, hypertension, aging, and many 
more [8,24,25,44,47,57,101].  Most notably, eNOS uncoupling acts as a significant 
contributor to vascular disease and impaired NO-production in the vascular endothelium. 
Under pathological conditions, eNOS can become uncoupled by increased ROS production 
in the vascular endothelium [38,69,94], reduced availability of its cofactor BH4 
[24,25,69,101,110] or increased expression of the enzyme arginase [38,47,57].  
In this study, we investigated the effects of fluid percussion-induced TBI on 
endothelial-dependent vasodilatory functions in a remote systemic tissue bed (the 
mesenteric microcirculation), 24 hours after injury. Based on the literature reviewed here, 
we hypothesize that endothelial dysfunction, as defined by impaired endothelial-dependent 
vasodilation, occurs after a TBI, due to dysregulation of either the NO or EDH pathways 









In this study, adult male Sprague-Dawley rats (300-350 g) were used to test the 
effects of TBI on mesenteric arteries.  Experimental TBI was induced by a fluid percussion 
injury model as previously described [71].  Briefly, a craniotomy was performed in 
anesthetized rats and a bolt attached to a fluid filled column was placed between the bregma 
and lambda landmarks on the skull.  Brain injury was induced by releasing a pendulum to 
create a pressure pulse that damages the brain. This method produces a mild and survivable 
brain injury keeping the dura intact and producing astrogliosis and neurological deficits 
[71]. Un-operated animals were used as controls for this study.  After a 24hr recovery 
period the rats were anesthetized by an intraperitoneal injection (i.p) of sodium 
pentobarbital (30 mg/kg) and then euthanized by decapitation. 
 
2.2.2 Isolation and pressurization of mesenteric arteries 
After euthanasia, the small and large intestine with attached mesenteric tissue was 
placed in ice cold (4 °C) physiological saline solution (PSS of the following composition: 
NaCl 118.5 mM, KCl 4.7 mM, KH2PO4 1.18 mM, MgCl2 1.2 mM, NaHCO3 20 mM, CaCl2 
2.5 mM, glucose 7.5 mM) and then pinned down on a sylgard plate.  Fourth-order resistance 
mesenteric arteries (<200 µM in diameter) were chosen for this study because they 
displayed more myogenic tone compared to larger diameter mesenteric arteries (1st-3rd 
order) [22].    Arteries were isolated from surrounding tissue and were mounted on 
opposing small glass pipettes and secured with suture material in a small vessel chamber 
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(Living Systems Instrumentation, St. Albans, VT, USA). Vessels were briefly cannulated 
to remove intraluminal blood before experimentation.  Arteries were pressurized using a 
pressure servo system (Living Systems Instrumentation, St. Albans VT, USA) to 80 mmHg 
with PSS induced by the proximal side of the mount and the distal end closed with a stop 
cock.  Vessels were allowed to equilibrate for 15 minutes at low pressure (10 mm Hg) 
before pressure was raised to 80 mm Hg to allow vessels to develop spontaneous myogenic 
contraction.   Endothelium integrity was tested in each vessel with the compound NS309 
(1 µM) which increases Ca2+ sensitivity to SKCa and IKCa channels.  Arteries that did not 
develop tone were discarded from the experimental series.  The chamber was continuously 
superfused with warmed PSS (37°, pH 7.4) which was bubbled with bioair (75% Nitrogen, 
20% Oxygen and 5% CO2).   The vessel chamber was placed on an inverted microscope 
with attached CCD camera and edge detection software (Ionoptix 6.0) to monitor lumen 
diameter changes.  The Ca2+ channel blocker diltiazem (100 µM) in Ca2+-free PSS was 
used to obtain passive diameter of vessels at the end of each experiment. 
 
2.2.3 Assessment of endothelial dysfunction following TBI 
ACh concentration response curves (CRC) were performed in mesenteric control 
and TBI arteries that spontaneously developed myogenic tone.  Arterial responses were 
measured with increasing logarithmic concentrations of two endothelium-dependent 
vasodilators ACh (1 nM to 1 µM) and bradykinin (BK) (30 pM to 300 nM). To test the role 
of EDHF in mesenteric arteries following TBI, arteries were incubated with the NOS 
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competitive inhibitor NG-nitro-L-Arginine (L-NNA, 100 µM) for 20-25 minutes prior to 
and during agonist treatment 
 
2.2.4 Assessment of NO contribution following TBI 
To test the role of NO in ACh induced vasodilation in TBI and control groups, EDHF 
antagonists apamine (30 µM) paxilline (1 µM) and charybdotoxin (200 nM)[103] were 
sequentially added to the superfusing bath for 10 minutes prior to ACh addition (1 µM). 
Apamine is a toxin derived from bees, and specifically inhibits SKCa channels.  Paxilline 
is a peptide derived from penicillium which blocks BKCa channels.  Charybdotoxin is 
obtained from scorpion venom and acts as a BKCa and IKCa channel blocker.  
In order to obtain the contribution of KCa to myogenic tone, all blockers were added to 
the bath as follows: paxilline, charybdotoxin, apamine.  Decrease in lumen diameter was 
calculated as a percentage of myogenic tone. ACh-induced dilation (1µM) was calculated 
in the presence of all three blockers as a percentage of passive to determine NO 
contribution.  
 
2.2.5 Pressure-induced constriction (myogenic tone) and measurement of L-NNA 
induced vasoconstriction. 
To determine whether TBI affects myogenic tone in mesenteric arteries, 
experiments were performed in pressurized arteries by increasing intraluminal pressure to 
80 mmHg in control and TBI groups and quantifying % tone in comparison to maximal 
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diameter achieved under passive conditions (Ca2+-free PSS and diltaiazem).  To study the 
role of the endothelium in myogenic response in this particular vascular bed, arteries were 
endothelium denuded; endothelium was disrupted by either introducing 1-2 mL air into the 
lumen of the arteries for 5 minutes or mechanical damage by carefully passing a hair 
through the vessel.  Removal of endothelium was determined by the lack of response to the 
SKCa/IKCa channel activator NS309 (1µM).  Only arteries with <15% dilation to NS309 
were considered as endothelium denuded.   
 
2.2.6 Sepiapterin Supplementation 
TBI and control arteries were incubated with L-sepiapterin (1 µM), a substrate for 
BH4 synthesis through the salvage pathway, separate from the de novo pathway of BH4 
synthesis.  Control and TBI vessels were incubated with sepiapterin for 30 minutes prior 
to a CRC of ACh was performed. Furthermore, the effect of sepiapterin on myogenic tone 
was also calculated in each experiment. 
 
2.2.7 Arginase inhibition and L-Arginine supplementation 
To rescue ACh induced vasodilations following TBI, mesenteric arteries from 
control and TBI animals were incubated with the specific arginase inhibitor Nω-hydroxy-
nor-Arginine (Nor-NOHA; 20 µM) or with the NOS substrate NG-amino-L-Arginine (L-
Arginine; 100µM) for 30 minutes or until vessel diameter was stabilized; then, increasing 




2.2.8 Smooth muscle sensitivity to NO donors and contractility of vascular smooth 
muscle 
To test the sensitivity of VSMC to NO after TBI in mesenteric arteries, the broad 
spectrum NOS inhibitor  L-NNA (100 µM) was superfused for 20 minutes or until the 
vessel diameter was stabilized, followed by increasing logarithmic concentrations of the 
NO donor spermine NONOate (1 nM to 1µM).   
SMC contractility was tested in control and TBI mesenteric arteries by introducing 
logarithmic concentrations of the analog of the endoperoxide prostaglandin H2 U46619 
(1nM to 1µM). 
 
2.2.9 Drugs and Reagents 
NS309 (6,7-Dichloro-1H-indole-2,3-dione 3-oxime) was purchased from Tocris 
(Minneapolis, MN), 100 mM stock aliquots diluted with DMSO were prepared prior to 
experimental series and were stored at -20°C.  ACh [2-(Acetyloxy)-N,N,N-
trimethylethanaminium chloride] and L-NNA [N5-(Nitroamidino)-L-2,5-
diaminopentanoic acid] were purchased from Sigma-Aldrich (St. Louis, MO).  ACh 
aliquots were diluted with Milli-Q water and stored at -20 °C and discarded after 1 month. 
L-NNA was stored in powder form at room temperature; dilutions were made in 1 M HCl 
and kept at room temperature.  Charybdotoxin was purchased from International Peptides 
and was diluted with MilliQ water.  Apamine and paxilline were purchase from Sigma-
Aldrich (Saint Louis, MO).  Aliquouts were made in either DMSO or milliQ water and 
were stored at -20 °C.  L-sepiapterin 2-amino- 7,8-dihydro-6-(2S-hydroxy-1-oxopropyl)-
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4(1H)-pteridinone was purchased from Cayman Chemical (Orlando, Florida) and stored in 
powder form at -20°C.  Fresh dilutions in DMSO were prepared immediately before vessel 
incubation.  Nor-NOHA was purchased from Cayman Chemicals (Ann Arbor, MI) and was 
diluted with DMSO and stored at -20°C.  L-Arginine was purchased from Sigma-Aldrich 
(Saint Louis, MO), dilutions were made with milliQ water and was stored at -20°C.  The 
NO donor, Spermine NONOate [(Z)-1-[N-[3-aminopropyl]-N-[4-(3-
aminopropylammonio)butyl]-amino]diazen-1-ium-1,2-diolate and U-46619 were 
purchased from Cayman Chemicals (Ann Arbor, MI).  Serial dilutions of spermine 
NONOate were made with .01 M NaOH and were stored at -20°C, and U-46619 dilutions 
were made in DMSO and stored at -20°C.  
 
2.2.10 Analysis and Statistics 
Myogenic tone was calculated as the percentage (%) decrease of the lumen diameter in 
comparison to Ca2+ free PSS in the following equation: Tone (%) = 
[(Dpassive−Dactive)/Dpassive]x100, where Dpassive = the (passive) lumen diameter of the artery 
in Ca2+-free PSS containing the vasodilators diltiazem (100 µM) and Dactive = the (active) 
lumen diameter of the artery in Ca2+-containing PSS. 
% Vasodilation was calculated as the difference in diameter before and after agonist 
administration normalized to maximum diameter in Ca2+ free PSS (Ddrug - Dbaseline / Dpassive 
- Dbaseline)x100. % Vasoconstriction was calculated as the difference in diameter before and 
after charybdotoxin, paxilline, apamine, and U46619 administration normalized to the 
baseline diameter before addition of drug (Ddrug - Dbaseline / Dbaseline)x100.  
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Values are represented as means ± standard error mean (SEM).  Concentration‐
response curves were calculated with GraphPad Prism software (version 6.03; GraphPad 
Software, Inc) to fit the Hill slope from the data (variable slope model) for each individual 
experiment and then averaged to obtain the mean and SEM values. Statistical comparisons 
were performed using GraphPad Prism. Because of generally small sample sizes (example 
n=5 to 12), the nonparametric test Mann Whitney was used for comparison between 2 
groups. We also used repeated measures analysis of variance (ANOVA) for the comparison 
of multiple groups at different concentrations. Statistical significance was considered at the 




2.3.1 Agonist-induced vasodilations in mesenteric arteries from control and TBI 
animals 
 
Measurement of the extent of vasodilation induced by the muscarinic-receptor 
agonist ACh is the standard assay for endothelial dysfunction in pressurized arteries.  To 
assess endothelial function following TBI, ACh concentration-response curves  (1 nM to 1 
µM) were performed in fourth order mesenteric arteries isolated from control and TBI 
animals and constricted with myogenic tone (Figure 2A).  ACh-induced vasorelaxation 
was significantly attenuated in arteries from TBI rats compared to control (Figure 2C) 
suggesting a compromised endothelial-dependent vasorelaxation following TBI (n= 6, 
P<0.0001, Two-way ANOVA).  Maximal dilation to ACh (1 µM) was severely diminished 
in TBI arteries compared to controls (59 ± 9% of passive diameter, n=6 vs 100 ± 1% of 
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passive diameter, n=6)).  LogEC50 values for control and TBI arteries were -7.4  ± 0.09 
(n=6)  vs -7.2 ± .43 (n=6), respectively, demonstrating a shift in the PD2 values in TBI.  
Arteries from TBI animals could not maximally dilate to ACh, Emax was impaired.  
In order to confirm the finding of endothelial dysfunction, and not simply 
downregulation of muscarinic receptors, we also performed concentration response curves 
with a different endothelial-dependent vasodilator bradykinin, which acts through 
bradykinin receptors. We performed a concentration-response curve of bradykinin (30 pM 
to 300 nM) in control and TBI arteries. Bradykinin (BK) induced vasodilations were also 
attenuated following TBI (n=5, Two-way ANOVA, P<0.0001).  With a shift in the 
sensitivity to BK LogEC50 values for control and TBI arteries were -9.0 ± 0.07 (n=5) vs -
8.1 ± 0.04 (n=5), respectively.  Arteries obtained from TBI animals dilated maximally to 
BK.  These data confirm that endothelial-dependent vasodilations are impaired in 
mesenteric arteries from TBI rats.  
 
2.3.2 EDHF contribution to ACh-induced vasodilation following TBI 
To determine which endothelial derived pathway was causing a lack of vasodilation 
in response to ACh, we investigated the role of both EDHF and NO in ACh-mediated 
vasodilation.  We evaluated the EDHF contribution by blocking the NO pathway with a 
broad NOS competitive inhibitor, L-NNA (100 µM) prior to and during ACh concentration 
challenge (1 nM to 1 µM) in both control and TBI arteries. In the presence of L-NNA (100 
µM), ACh-induced dilations were attenuated in controls (1 µM ACh, 58 ± 12% of passive 
diameter, n=7, P<0.0001, Two-way ANOVA) but not in the TBI group (1 µM ACh, 63 ± 
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8% of passive diameter, n=6, Two-way ANOVA, n.s.) (Figure 2D), suggesting the EDHF 
component is intact in mesenteric arteries following TBI.  These data indicate that the 
contribution of NO to ACh-induced dilations is blunted after TBI, suggesting either a lack 







Figure 2: Endothelial dysfunction was assessed in arteries from TBI rats by an endothelial 
dependent agonist ACh. Representative trace of arteries from control and TBI animals (A) ; arteries were 
allowed to develop myogenic tone at 80 mmHg, and were then subjected to stepwise increases of the 
muscarinic receptor agonist acetylcholine (ACh). (B) ACh concentration curves were performed in the 
presence of NOS inhibitor L-NNA (100 mM) dilations. (C) Summary data of ACh response curve in control 
and TBI groups. (D) Summary data of ACh response curve in the presence of L-NNA in control and TBI.  












Figure 3: Bradykinin induced vasodilations are attenuated in mesenteric arteries following TBI. 
Concentration response curves were performed in pressurized arteries from control and TBI rats in a pressure 
myograph system (A)(Two way ANOVA p<0.0001). (B) Response increased concentrations of bradykinin 
in the presence of the NOS inhibitor L-NNA. Vasodilation (% vasodilation) was quantified as the measured 
vessel diameter normalized to maximal relaxation of the same artery in Ca2+-free buffer   
 
2.3.3 NO contribution to ACh-induced vasodilation following TBI 
 
To further investigate the roles of endothelial dependent vasodilations in control 
and TBI arteries, the EDH pathway was inhibited with the pharmacological blockers: 
apamine (300 nM), charybdotoxin (200 nM), and paxilline (1 µM) (Figure 4A-B).  ACh-
induced dilation (1 µM) in control arteries (Figure 3A) were reduced, but not blocked (17 
± 3% of passive diameter, n=10), implying that in control groups the NO pathway is intact 
(Figure 3A).  However, the dilation to ACh (1 µM) in the presence of these blockers was 
partially inhibited in TBI arteries (9 ± 3% of passive diameter, n=8, Mann-Whitney test, 
P<0.05) compared to controls (Figure 4C).  The effect of SKCa, IKCa and BKCa channel 
blockade on basal tone was also tested in TBI and control arteries.  We found no difference 
between groups (Figure 4D). Overall this indicates that in the absence of EDHF 





Figure 4: Endothelial dysfunction following TBI involves impairment in NO-component of 
vasodilation: Representative trace showing control (A) and TBI (B) arteries in the presence of 
pharmacological blockers of EDHF vasodilatory pathways. Arteries were incubated in the presence of 
apamin (300 nM), charybdotoxin (200 nM) and paxilline (1 µM) prior to addition of ACh (1 µM). 
Vasodilation (% vasodilation) was quantified as the measured vessel diameter normalized to maximal 
relaxation of the same artery in Ca2+-free buffer.  (C) Summary data show that TBI arteries displayed a 
significant diminution in the NO component of ACh-induced dilation compared to controls (Mann-Whitney 







2.3.4 NO release or production is decreased in TBI mesenteric arteries 
The basal production of NO in mesenteric arteries was measured indirectly by 
measuring the constriction induced by the NOS competitive inhibitor L-NNA (100 µM) 
(Figure 4).  L-NNA induced vasoconstriction was attenuated in arteries from TBI rats (3 ± 
2% change in baseline, n=9) compared to controls (8 ± 1% change in baseline, n=12) 
(Mann-Whitney test, P<0.05) (Figure 5C), indicating a decreased basal NO production in 
TBI arteries.   
Pressure-induced constriction (myogenic tone) was also measured in arteries from 
control and TBI animals (Figure 5D).  Arteries from TBI rats showed enhanced myogenic 
tone compared to controls at 80 mmHg, respectively (40 ± 9 % tone, n=6 vs 27 ± 2% tone, 
n=10).  Denuded mesenteric arteries from control rats displayed an enhanced myogenic 
tone similar to arteries from TBI rats (42 ± 7% tone, n=6 vs 39 ± 3% tone, n=5, n.s.) 
indicating that in this vascular bed, a tonic release of NO counterbalances the myogenic 
response.  Endothelium denudation had no effect on myogenic tone development within 
the TBI group.  Inhibition of NO production with L-NNA (100 µM) normalized the level 




Figure 5: Decreased NO bioavailability and increased myogenic tone in TBI arteries: Representative 
trace of control (A) and TBI (B) arteries exposed to the nitric oxide synthase inhibitor L-NNA (100 nM), the 
resulting vasoconstriction was quantified as the luminal diameter normalized to the baseline diameter of the 
same vessel (% change in baseline). (C) Summary data of % constriction in response to L-NNA in control 
and TBI arteries (T-test, P<0.05). (D) Summary data of myogenic tone in TBI and control arteries in intact 











2.3.5 Effect of L-Sepiapterin supplementation on ACh-induced dilation 
Previous studies have reported that deficient NO production in vascular disease has 
been linked to eNOS uncoupling by oxidation of the NOS cofactor BH4 by ROS.  To test 
whether the lack of cofactor contributes to a decreased eNOS activity  and uncoupling of 
eNOS, we added an exogenous substrate for BH4 synthesis, L-sepiapterin (1 µM)[89].   
Concentration-response curves of ACh (1 nM to 1 µM) were performed in control and TBI 
vessels in the presence of L-sepiapterin (1µM) (Figure 6).  L-sepiapterin supplementation 
rescued the maximal dilation to ACh (1 µM) in TBI arteries (91 ± 1% of passive diameter, 
n=5 vs 86 ± 6% of passive diameter n=5)  (Figure 5B).  However, L-sepiapterin was not 
able to rescue the entire ACh concentration response curve in TBI.  L-sepiapterin (1 µM) 
incubation also had an effect on ACh induced vasodilations in control vessels, attenuating 
ACh induced vasodilations from 30nm-1 µM (Figure 6A), suggesting that addition of BH4 
into control arteries disrupts normal vasodilatory function.  The effect of sepiapterin on 
myogenic tone on TBI arteries was tested.  We found no difference in tone between TBI 
and control vessels (32 ± 1% of tone vs  32 ± 2% of tone) (Figure 6C).  Sepiapterin was 
able to restore arterial tone in arteries from TBI animals compared to controls.  Overall, 
Sepiapterin partially restored ACh vasodilations (Emax) and fully restored myogenic tone 




Figure 6: The BH4 precursor L-sepiapterin partially restored endothelial dependent dilations in TBI 
arteries: Sepiapterin (1 µM) was incubated in control (A) and TBI (B) vessels before and during ACh 
response curves at 80mmHg. (C) Summary data of ACh CRC in the presence of sepiapterin. (D) 
Measurement of the effect of sepiapterin on myogenic tone in Control and TBI arteries. % Tone was 















2.3.6 L-Arginine supplementation and arginase inhibition rescues ACh-induced 
vasodilations in arteries from TBI rats 
 
The partial rescue of BH4 synthesis through exogenous supplementation of the 
substrate sepiapterin lead us to change our focus from the cofactor and look at the eNOS 
substrate L-arginine.  Control and TBI arteries were incubated with L-arginine (100 μM) 
before and during an ACh concentration response curve (1 nm to 1 µM).  Supplementation 
with L-arginine rescued ACh-induced dilations in TBI arteries compared to TBI arteries 
without supplementation (1 µM ACh; 98 ±1% of passive vs 59 ±9% of passive) (Figure 
7D).   
Previous studies have shown that the enzyme arginase competes with eNOS for L-
arginine and therefore may contribute to endothelial dysfunction [8,38,47,101,115].  
Therefore, we tested ACh-induced dilations in the presence of the arginase inhibitor nor-
NOHA (20 μM) in control (Figure 7A) and TBI (Figure 7B) arteries.  Incubation with nor-
NOHA rescued ACh-induced in TBI compared to TBI arteries without rescue (1 µM ACh; 
98 ±1% of passive vs 59 ±9% of passive).  These data indicate that increases of arginase 
activity and associated reduction in cellular L-arginine levels in the vascular endothelium 






Figure 7: Supplementation of L-arginine and inhibition of arginase restores endothelial function in 
mesenteric arteries following TBI: ACh induced concentration response curve in the presence of the 
specific inhibitor of arginase Nor-NOHA (20 µM) (Nω-hydroxy-nor-Arginine) in control (A) and TBI (B) 
arteries. (C) Summary data showing ACh CRC in the presence of Nor-NOHA, (D) Control and Mesenteric 
arteries subjected to ACh CRC in the presence of L-arginine. Dotted lines represent control arteries 












2.3.7 Vascular smooth muscle sensitivity to NO and contractility 
To determine if the vascular smooth muscle sensitivity to NO was altered following 
TBI, VSMC sensitivity was tested by performing a concentration-response curve with the 
NO-donor spermine-NONOate (1 nM to 1 µM) in the presence of L-NNA (100 µM) to 
prevent endogenous NO production.  Spermine NONOate elicited endothelial-independent 
vasodilations which were not significantly different between groups (n=5-6, Two-way 
ANOVA, p> .05)  (Figure 8A). 
To investigate if VSMC constriction responses were changed in TBI mesenteric 
arteries, contractility was tested by performing concentration response curves with the 
agonist U-46619 (3 nM to 1 µM) (Figure 8B) at low pressures to avoid the contribution of 
myogenic tone (40 mm Hg).  U-46619 elicited VSMC constrictions were were similar 
between groups (n=4, Two-way ANOVA, p>.05) 
An alternate hypothesis for impaired NO production would be decreased eNOS 
expression. To further investigate whether TBI affects eNOS expression, eNOS mRNA 
levels were measured in isolated fourth order mesenteric arteries from control and TBI rats.  
Quantitative-PCR (qPCR) showed that there was no difference of eNOS mRNA levels 






Figure 8: Smooth muscle sensitivity to NO and functional contractility is not altered in TBI vessels: 
(A) Smooth muscle sensitivity to NO was determined using the NO donor Sperimine NONOate in the 
presence of L-NNA in control and TBI arteries. (B) Smooth muscle contractility was determined by 
performing U-46619 CRC in control and TBI arteries. (C) mRNA expression was measured in Control and 












This is the first study conducted to address the effects of TBI on areas remote from 
the site of injury. This study begins to address how TBI has a peripheral effect on 
vasculature in addition to the well-documented cerebral effect.  We hypothesized that TBI 
causes profound changes in mesenteric arteries resulting in a loss of endothelial-dependent 
vasodilation 24 hours after brain injury.  We were able to demonstrate endothelial 
dysfunction in TBI mesenteric arteries by performing concentration response curves for 
two different endothelial-dependent vasodilators, the muscarinic agonist ACh and BK.  We 
found that endothelial-dependent dilations to both agonists were impaired in fourth-order 
mesenteric arteries 24 hours after TBI and that the NO pathway is impaired following TBI; 
however the EDHF pathway remained intact, providing the predominant endothelium-
dependent vasodilatory mechanism in arteries obtained from TBI animals.  We also studied 
whether eNOS uncoupling could be responsible for the lack of eNOS-mediated dilations 
following TBI which has been shown in other animal models of diabetes [100], 
hypertension [69] and obesity [116].  Supplementation with the BH4 precursor sepiapterin 
partially rescued ACh-induced vasodilations (1 µM) and restored myogenic tone in arteries 
from TBI rats.  Furthermore, we found that arginase inhibition with nor-NOHA and 
supplementation with L-Arginine rescued ACh-induced vasodilations in mesenteric 






Our functional assay of ACh-induced dilations demonstrated that endothelial-
dependent vasodilations were impaired in fourth-order mesenteric arteries 24 hours after 
TBI (Figure 2).  When the contribution of NO was abolished by L-NNA, ACh-induced 
vasodilations were partially inhibited in control mesenteric arteries, indicating that ACh-
induced vasodilation involves both NO and EDHF pathways (Figure 6).  However, NOS 
inhibition had no effect in TBI arteries, suggesting the lack of NO bioavailability and 
contribution to ACh-induced dilations following TBI.  The remaining dilation to ACh in 
the presence of L-NNA (100 µM) shows the EDHF component of ACh-induced dilations, 
which implicates the contribution of KCa channels (SK and IK) also present in the vascular 
endothelium which are activated by a rise in intracellular cytosolic Ca2+ upon agonist 
stimulation [108].   As Figure 1 shows, ACh-induced dilations measured in TBI rats 
mimicked those of control in the presence of L-NNA (100 µM) suggesting that the EDHF 
component is the only vasodilatory pathway that remains intact following TBI in this 
vascular bed.  Vasoconstriction in response to apamine, charybdotoxin, and paxilline in 
control and TBI arteries was similar, further demonstrating that the EDHF pathway is intact 
following TBI (Figure 4).  From these data we can conclude that the EDHF pathway is 
intact in mesenteric arteries following TBI.   
In control arteries, EDHF represents ~50% of the maximal ACh-induced 
endothelial-dependent vasodilation (Figure 2C).  This finding contradicts previous studies 
that suggest small resistance arteries rely mostly on EDHF (~75%) for vasodilation 
[28,54,68,97];  these differences in EDHF contribution could be due to different species or 
to the arterial diameter elected for study.   In other models of disease such as diabetes, 
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disruptions of the EDHF pathway have been reported [72,106,112].  In this regard, our data 
do not support the findings from Leo et al, where they showed that both the NO- and 
EDHF-mediated relaxations were significantly diminished in mesenteric arteries from 
streptozotocin-induced diabetes animal model [72]. This can be attributed to the difference 
in disease model (diabetic vs TBI) or possibly chronicity of the disease pathway (TBI acute 
onset and diabetes long term).  However, a study conducted on mesenteric arteries in an 
ischemia-reperfusion model, where they showed NOS inhibition attenuated ACh-response 
by ~50%, does support our findings that the NO-component contributes more to ACh-
induced dilations in rat mesenteric arteries than previously mentioned [77].   
We also used a different agonist to explore whether or not the endothelial 
dysfunction seen after TBI is unique to the muscarinic receptor ACh.  Bradykinin (BK), an 
agonist of the B2 receptor which is also located in the vascular endothelium, induced 
vasodilation in control and mesenteric arteries (Figure 3).  BK-induced vasodilations were 
significantly attenuated in TBI arteries without altering Emax (Figure 3). This may be 
indicative of a different mechanism of endothelial-dependent vasodilation in response to 
bradykinin or that the ACh muscarinic receptor is dysfunctional in TBI mesenteric arteries.  
A study done in rat mesenteric arteries in vivo showed that the NOS inhibitor L-NAME 
plus indomethacin did not inhibit BK-induced blood flow [87], implying that BK dilates 
vessels mainly through the EDHF pathway.  Contradicting this, previous studies have 
proven that BK-induced dilation in mesenteric arteries functions through both the NO and 
EDHF pathway and can be attenuated by the NOS inhibition [68].  However, the inability 
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of vasculature to dilate in the presence of the agonist ACh or BK has been a reference for 
the loss of vascular integrity specifically for endothelial-dependent dysfunction. 
When the contribution of EDHF was inhibited with apamin, charybdotoxin and 
paxilline, relaxations to ACh (1 µM) were significantly decreased in TBI compared to 
normal arteries, further suggesting that the contribution of NO was impaired by brain injury 
(Figure 3).  To measure basal NO production, the constriction to L-NNA was measured in 
arteries from control and TBI animals. Control arteries expectedly constricted ~20% 
(compared to tone) in response to L-NNA which is consistent with previous studies 
[61,72,81].  However, constriction to L-NNA in arteries taken from TBI animals was 
significantly decreased compared to controls (Figure 6C) indicating that basal level of NO 
production is decreased in mesenteric arteries from TBI rats demonstrating an impaired 
NO pathway in systemic circulation following TBI.  In comparison, in cerebral arteries NO 
production is increased following TBI compared to controls [111].  This might be a 
compensatory mechanism of traumatic brain injury found centrally and not peripherally.   
Vascular tone at 80 mm Hg was also measured in mesenteric arteries from control 
and TBI groups.  TBI arteries displayed an enhanced myogenic tone compared to controls 
(Figure 4D).  Denuded TBI arteries had no difference in myogenic tone compared to intact 
TBI, however, control denuded arteries displayed an enhanced myogenic tone similar to 
that of TBI arteries.  Inhibition of NOS with L-NNA in control arteries diminished the NO 
component and was similar to the myogenic response of TBI arteries, demonstrating that 
increased myogenic tone in TBI rats is due to an impaired function of eNOS.  Although 
the role of endothelial vasoactive factors in modulating myogenic tone has been 
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controversial, in this study we have correlated the lack of NO production with an increase 
of myogenic tone.  This increase in basal constriction was not due to altered sensitivity to 
NO (Figure 7A) or to increase of VSMC contractility (Figure 7B) since both remained 
intact in TBI mesenteric arteries. 
After confirming endothelial dysfunction in TBI mesenteric arteries, we studied 
whether a decreased concentration of the essential eNOS cofactor BH4 promoted eNOS 
uncoupling, resulting in a lack of NO-derived vasodilations in response to ACh. 
Supplementation with sepiapterin, an intermediate in the salvage pathway of BH4 
synthesis, showed partial rescue to ACh-induced vasodilation at the maximal concentration 
of 1 µM (Figure 6C) and restored myogenic basal tone compared to controls (Figure 6D) 
but was unable to rescue concentrations of 1 nM-300nM of ACh.  Sepiapterin rescue at 
only 1 µM ACh could imply that the muscarinic receptor sensitivity to ACh is impaired in 
mesenteric arteries following TBI.  Sepiapterin rescue of maximal dilation is consistent 
with the obesity model of vascular disease, where 3rd order mesenteric arteries were 
rescued from attenuated vasodilations to ACh at 1 μM [89].  However, a concentration 
response curve was not performed in this study so we were unable to compare our results 
obtained at lower concentrations of ACh.  
 Recent data suggest that the ratio of BH4:BH2 may be a more important 
determinant of eNOS function than the absolute concentration of BH4 [56,109,110].  In an 
oxidative environment BH4 can be oxidized to BH2 which has a higher binding affinity to 
eNOS than BH4.  Although BH4 oxidation was not investigated in this study, increased 
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concentrations of BH2 may explain why supplementation with sepiapterin was not able to 
rescue eNOS function in TBI arteries.  On the other hand, high concentrations of 
sepiapterin could also uncouple eNOS leading to generation of superoxide O2−.  Recently, 
it has been shown that BH2 and sepiapterin inhibit NOS in vitro by displacing the pre-bound 
BH4 with >80% efficiency [58].  BH2 and sepiapterin are metabolites that accumulate in 
patients with variants of BH4 deficiency, and it has been suggested that they may potentiate 
the superoxide formation during the uncoupled reaction of NOS [9,119].  
The BH4 precursor sepiapterin was unable to rescue the concentration-response 
curve of ACh which lead us to investigate whether the eNOS substrate, L-arginine, could 
explain compromised ACh-induced vasodilation following TBI.  We discovered that 
exogenous supplementation with the NOS substrate L-arginine (100 μM) did rescue ACh-
induced vasodilations in TBI arteries (Figure 7D).  Since arginase and eNOS share the 
same substrate, an increased arginase activity or expression could decrease L-arginine 
bioavailability.  In this regard, several studies have shown the role of arginase in 
endothelial dysfunction and eNOS uncoupling under different physiological and 
pathological states [8,44,47,57,90,101].  Incubation with the specific inhibitor of arginase 
nor-NOHA (20 µM) rescued ACh-induced dilations in our model of TBI (Figure 7A-C).  
Further studies measuring total arginase expression using western blot analysis will be 
necessary to determine if increased arginase is responsible for uncoupling eNOS and 
promoting endothelial dysfunction following TBI.  Despite the selectivity of arginase 
inhibitors, it has been reported that nor-NOHA can potentially inhibit eNOS in mesenteric 
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arteries; supplementation of L-arginine + nor-NOHA however rescued ACh-induced 
vasodilation in control mesenteric arteries [53].  
In our study, we did not find increased eNOS expression in mesenteric arteries 
following TBI (Figure 8).  Similar findings were seen in an ischemia reperfusion model 
where eNOS protein level expression measured in mesenteric arteries was also not 
increased. Also, in an obesity model, eNOS expression was not different between control 
and disease groups, however, eNOS activation measured by phosphorylation was 
decreased, contributing to impaired endothelial-dependent dilations [116].  In mesenteric 
arteries from a rat model of obesity it was reported that there was no difference in total 
eNOS expression; however, eNOS dimerization suggested that eNOS was acting in a 
monomeric state which was responsible for uncoupled behavior [72].  Although we 
determined that eNOS expression is not altered following TBI, it is also possible that the 
activity of eNOS is altered by post-translational modification or uncoupling and un-
dimerization.  
Finally, because there has been some controversy about the role of endothelial 
vasoactive factors in regulating myogenic tone, we also tested the vascular smooth muscle 
function to rule out VSMC dysfunction as mechanisms of impaired vasodilation (Figure 
7).  We tested both vasodilation in response to NO and contractility in response to the 
thromboxane agonist U-46619, and found no differences in VSMC function at 24 hours 
after TBI compared to controls.  Thus, the increase in vascular tone after TBI is not due to 
change in sensitivity to NO (Figure 8A) or altered contractility of VSMC (Figure 8B) but 
due to the dysfunctional endothelium. 
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The vascular effect seen remote from the site of injury might suggest the 
contribution of circulating factors such as histones, polyphosphates or other unidentified 
factors.  Recently, they have been implicated in TBI [66] and other pathological states like 
sepsis [114] or lung-associated injury [1]. Whether they cause endothelial damage to 
resistance-sized arteries remains unclear. In summary, this study demonstrates that fluid 
percussion induce TBI causes profound vascular systemic damage to mesenteric arteries, 
leading to a dysfunctional TBI induces a release of circulating factors into the systemic 
circulation, causing a dysfunctional endothelial-dependent vasodilation in mesenteric 
arteries and increased arginase activity (Figure 9).  Arginase in turn competes with eNOS 
for L-arginine; consumption of L-arginine by arginase starves eNOS causing a loss of 
eNOS function.  This in turn diminishes NO-production in the vascular endothelium 
resulting in a compromised endothelial-dependent vasodilation to agonist stimulation 
(ACh and BK) and increased myogenic tone due to a decreased basal NO production. 
 
 
2.5 Conclusions and Future Directions 
 
Traumatic injury to brain tissue causes release of circulating factors normally 
sequestered from the circulation, along with massive catecholamine release and 
elevations in ROS.  Several studies have shown that TBI can lead to cardiovascular 
pathology, but to our knowledge, there are no studies focusing specifically on the 
vascular endothelium after TBI.  This is an important area for research, because 
endothelial dysfunction could explain the hypertension, coagulopathy and impaired 
barrier functions of pulmonary and cerebral vessels, often seen after trauma.  
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Overall, this study demonstrates 24 hours after a traumatic brain injury, systemic 
resistance vessels show signs of endothelial dysfunction, manifest as impaired 
endothelial-dependent vasodilation. This appears to be due to an increased activity or 
expression of arginase activity in the endothelium.  This increase in arginase activity or 
expression subsequently leads to competition for L-arginine, limiting the ability of eNOS 
to produce of NO (Figure 9).  These results have important clinical implications. 
Resistance sized arteries which are extremely important in regulating blood pressure, 
circulating blood volume, and the production of anti-coagulant factors.  This damage to 
vascular endothelium could contribute to the dysfunctional coagulation factors seen in 
patients after trauma.   Thus, our data suggests that arginase inhibition may be a potential 
therapeutic target to rescue endothelial function in TBI patients.  
Future studies can be performed to determine if the activity of eNOS is altered by 
post-translational modification through Western blot analysis can determine if eNOS is 
acting in a coupled or uncoupled form, or if its active form (phosphorylated) is being 
expressed.  Also, it is unknown if the arginase enzyme has an increased protein 
expression in the endothelium or if its activity is increased by post-translational 
modification.  This can be later determined with western blot analysis of protein levels 
and phosphorylization of arginase.  The isoform of arginase can be determined by 
immunohistochemistry of fixed sections of endothelium.  Further studies using the slit 
open artery preparation (Figure 10) incubated with the fluorescent indicator DAF-2 DA 
of 4th order mesenteric arteries can help distinguish if the production of NO is altered 
following TBI.  To test if there is an increased production of ROS in the mesenteric 
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vascular endothelium, further studies using immunohistochemistry in control and TBI 
arteries could be performed.  
 
 
Figure 9: Schematic for endothelial dysfunction following TBI: Traumatic Brain Injury causes a release 
of circulating factors into the systemic system causing an increase of arginase activity or expression in 
vascular endothelium. Increases of arginase introduces a competitive environment for L-arginine, starving 
eNOS for L-arginine and causing eNOS uncoupling. eNOS can no longer produce NO, this leads to a 











We acknowledge the limitations of this study. One possible limitation is the 24 
hour time point of this study.  We recognize that systemic pathophysiological outcomes 
of TBI can last for up to two weeks after injury.  However, we chose one time point to 
ensure consistency of injury and outcome.  Second, only male Sprague Dawley rats were 
investigated in this study and the findings cannot be generalized to the female rat 
population due to the neuroprotective mechanisms in the female rat [2,27].  Third, we did 
not assess the prostacyclin pathway of endothelial-dependent dilations due to various 
accounts that have shown that the addition of the cyclooxygenase (COX) inhibitors has 
no effect on ACh-induced vasodilations in control arteries [89,97,112].  Specifically in 
rat mesenteric arteries, the contribution of the prostacyclin pathway in endothelial 
mediated vasodilation is controversial.  However, other models of disease have shown a 
tendency of an increased cyclooxygenase derived products such as PGI2 when there is an 
inhibited or impaired NO contribution [68,72].  Fourth, we did not explore the levels of 
ROS because it was beyond the scope of this project. It is apparent that ROS may play a 
role in mesenteric artery dilation following TBI.  ROS have been a common denominator 
when studying endothelial dysfunction in vascular disease and is a hallmark of 












CHAPTER 3: SUPPLEMENTARY METHODS AND RESULTS 
 
 
3.1 Slit open preparations 
 
To assess basal production of NO in control animals, mesenteric arteries were 
dissected from surrounding tissue and were pinned down and slit open on a sylgard plate 
with the endothelium facing upwards (Figure 10) [111].  The artery was incubated with the 
NO fluorescent indicator assay 4.5-diaminofluorescein (DAF-2 DA; 10 µM) for 1 hr at 
32°C in the dark and was then imaged with a spinning disk confocal microscope at 30 
frames/sec as previously described [111].  The vessel was superfused with oxygenated PSS 
and warmed to 37°C for 15 minutes before recordings to allow deesterfication of the 
fluorescent indicator.  Fluorescence intensity and pseudocolor images were analyzed with  
a custom software (Sparkan, Dr. Bonev, University of Vermont).  Unfortunately an 
increase of NO production in the presence of the muscarinic receptor ACh was not easily 
detected in control arteries.  We speculated that the reason for this may be that NO release 
in mesenteric arteries due to ACh was too small to detect with the DAF-2 DA which has a 
detection limit of 2-5 nM.  The viability of the preparation may have been compromised 
during the slitting open and pinning; over stretching the vessel may have damaged or torn 





Figure 10: NO production in the endothelium from slit open arteries assessed by DAF-2 fluorescence: 
en face preparation of 3rd order control mesenteric arteries showing NO staining indexed by DAF-2. Addition 
of NO donor Spermine (10 µM) slightly increased the NO production in endothelium. 
 
3.2 Cryostat sections 
Fourth order mesenteric arteries were dissected and were briefly cannulated to 
remove intraluminal blood before freezing.  Arteries were placed in OCT freezing medium 
and then frozen in 2-methyl-butane chilled with dry ice for 30 sec.  Frozen sections (100 
uM) were made with a cryostat; the sections were then incubated with 10 μM DAF-2 DA 
for 30 minutes at room temperature (Figure 11).  Negative controls were not incubated with 
DAF-DA, control and TBI arteries were incubated with DAF-2 DA and were imaged, 
control and TBI arteries were challenged with ACh (100 μM) and imaged.  These data were 
not incorporated due to the difficulty of viewing the endothelium in the arterial cross 
sections.  Although overall NO in the artery seems to be elevated in the controls compared 
to TBI, we decided not to continue with this technique due to the lack of proper 





Figure 11: NO production in fresh (unfixed) frozen sections of mesenteric arteries: NO production 
indexed by the fluorescent indicator DAF-2 DA in 100 µm sections of mesenteric arteries in control (A) and 
TBI (D) arteries (n=1). Application of ACh (100 µM) on both groups (B & E), Negative Controls showed 
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